SB 875 Wisconsin Senate · 2023-2024 Regular Session

Relating to: excepting xylazine testing materials from the definition of drug paraphernalia and civil and criminal liability exemptions for distributing and administering xylazine testing products.

Bill status signed all 5 stages cleared
Introduction
Jan 2024
Committee Review
Feb 2024
Senate Passage
Feb 2024
Assembly Passage
Feb 2024
Signed into Law
Mar 2024
Introduced Jan 5, 2024 Signed Mar 27, 2024
Floor votes

How they voted

This bill passed the Senate by voice vote (no roll call recorded).
Full legislative history

Actions timeline

Total actions
31
Key actions
5
Committee
3
Mar 27, 2024
Signed into law
Report approved by the Governor on 3-26-2024. 2023 Wisconsin Act 217
upper
Feb 20, 2024
Lower · Passed
Read a third time and concurred in
lower
Feb 15, 2024
Lower · Passed
Placed on calendar 2-20-2024 by Committee on Rules
lower
Feb 14, 2024
Committee
Read first time and referred to committee on Rules
lower
Feb 13, 2024
Upper · Passed
Read a third time and passed
upper
Feb 2, 2024
Upper · Passed
Report passage recommended by Committee on Mental Health, Substance Abuse Prevention, Children and Families, Ayes 5, Noes 0
upper
Jan 5, 2024
Introduced
Introduced by Senators James, Agard, L. Johnson, Pfaff, Roys, Spreitzer and Larson; cosponsored by Representatives Kitchens, Billings, C. Anderson, Behnke, Conley, Considine, Dittrich, Duchow, Gundrum, Jacobson, Mursau, Myers, Nedweski, Ohnstad, Ortiz-Velez, Palmeri, Rozar, Shankland, Sinicki and Subeck
upper
7 primary · 0 co-sponsors

Sponsors